OBJECTIVES:This study compared efficacy and safety of fluticasone (FL) with budesonide (BUD) and beclomethasone (BDP) in 1:2 dose ratio in the treatment of bronchial asthma.
METHODS:
Comparison was based on randomized controlled trials (RCTs) identified by means of systematic review, carried out according to the Cochrane Collaboration guidelines and Agency for Technology Assessment in Poland. The most important medical databases (EMBASE, MEDLINE and CENTRAL) were searched. Two reviewers independently selected trials, assessed their quality and extracted data. Head-to-head comparisons were performed. [-0.19; -0.03]) . No significant differences in safety outcomes were found between FL and BDP.
RESULTS
CONCLUSION: Fluticasone in comparison with budesonide and beclomethasone in dose ratios 1:2 provides improvement in spirometric parameters and in comparison to budesonide descreases risk of asthma exacerbations. Safety profiles of fluticasone seems to be comparable both with budesonide and beclomethasone.
